Nesina Lawsuit

Nesina Lawsuit
Patients who take Nesina to treat Type 2 diabetes may face a higher risk of pancreatitis and pancreatic cancer. Nesina lawsuits are also being investigated on behalf of patients who were hospitalized with heart failure while using this incretin mimetic medication.

Nesina Legal Investigation

The nationwide law firm of Bernstein Liebhard LLP is now offering free legal reviews to individuals who were diagnosed with pancreatitis, pancreatic cancer or heart failure while using Nesina. The Firm also offers complimentary consultations to those who experienced similar complications while using Kazano or Oseni, Type 2 diabetes drugs that also contain alogliptin. To learn more about filing a Nesina lawsuit, please call (888) 994-5118 to discuss your case with a member of our legal team.

Nesina: What’s The Problem?

Nesina (alogliptin) is an incretin mimetic used in conjunction with diet and exercise to lower blood glucose levels in patients with Type 2 diabetes. The medication slows the inactivation of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic peptide). These two incretin hormones play a role in regulating blood sugar.

Incretin mimetics, which along with Nesina include medications like Victoza, Januvia and Byetta, have proven to be a controversial class of medications. In fact, the British Medical Journal concluded in 2013 that the pancreatic risks associated with incretin mimetics may have been downplayed by the pharmaceutical industry. The BMJ also faulted the FDA and European regulators for failing to aggressively address these concerns. Read More

Incretin Mimetics and Pancreatitis

  • 2011: The journal Gastroenterology published a study which suggested that patients who use incretin mimetics had six times the risk of developing pancreatitis than patients using other diabetes medications. Pancreatitis is an inflammation of the pancreas that can lead to hospitalization and death. Long-term pancreatitis is also a risk factor for pancreatic cancer.
  • 2013: Johns Hopkins researchers reported that patients taking Type 2 diabetes drugs in the same class with Nesina were twice as likely to suffer from pancreatitis that required hospitalization.

Incretin Mimetic and Pancreatic Cancer

  • 2011: The authors of the Gastroenterology study also concluded that the findings “raised caution about the potential long-term actions of these drugs to promote pancreatic cancer”. They called for more research into the possible connection.
  • 2013: FDA announced that it was investigating the entire incretin mimetics class, after a study discovered inflammation of the pancreas and pre-cancerous cell changes in the pancreatic tissue taken from patients who had used the medications. However, the agency has so far been unable to confirm a link between these drugs and pancreatic cancer.

Nesina and Heart Failure

In April 2015, a panel of FDA advisors recommended that new information be added to the Nesina label regarding a possible increased risk of heart failure. The panel based its recommendation on the results of a clinical trial known as EXAMINE.

Legal Help Now Available for Those Harmed by Nesina

Legal assistance is now available for Nesina patients who have been diagnosed with pancreatitis, pancreatic cancer or heart failure. To learn more, please contact Bernstein Liebhard LLP at (888) 994-5118.

  1. BMJ (2013) “Has pancreatic damage from glucagon suppressing diabetes drugs been underplayed?”
  2. Gastroenterology (2011) Pancreatitis, Pancreatic, and Thyroid Cancer With Glucagon-Like Peptide-1–Based Therapies
  3. com (2013) “New generation of diabetes drugs raising more concerns”
  4. FDA (2013) “FDA Drug Safety Communication: FDA investigating reports of possible increased risk of pancreatitis and pre-cancerous findings of the pancreas from incretin mimetic drugs for type 2 diabetes”
  5. com (2015) “FDA Panel Backs New Safety Warnings on Two Diabetes Drugs”
Last Modified: April 13, 2016

Get the latest news and litigation updates about this case by following us on Facebook. Click the "Like" button below.


Follow Us on Google+ on Facebook on LinkedIn on Twitter on YouTube on Pinterest

Skip to content